Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Metabolex, a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, has executed a research collaboration with Takeda San Francisco (TSF), a wholly owned subsidiary of Takeda Pharmaceutical Company.
Subscribe to our email newsletter
Metabolex is expected to work with TSF on the evaluation and validation of protein targets for the development of biological products. Metabolex will provide novel protein targets discovered through the use of Metabolex’s target discovery technologies.
Harold Van Wart, president and CEO of Metabolex, said: “We are very excited about this partnership with TSF, Takeda’s center of excellence for antibody research. The collaboration brings together Metabolex’s expertise in diabetes and metabolic disease targets with TSF’s deep strength in antibody drug discovery and non-clinical development.”